Literature DB >> 2607149

Mouse strains with typical mammalian levels of complement activity.

G L Ong1, M J Mattes.   

Abstract

Common laboratory mouse strains have very low complement levels relative to humans, rats, guinea pigs, rabbits and other mammals, which limits the value of the mouse as an experimental model. We therefore tested serum complement levels of 43 mouse strains and 11 rat strains, for the purpose of selecting a convenient laboratory animal having high complement levels. Total complement activity was determined with both erythrocytes and human tumor cells as targets. Eight mouse strains were identified that have complement levels comparable to those of other mammals. These mouse sera lyse tumor cell targets as well as sera from humans, rats or guinea pigs, although they are somewhat less active than rabbit sera. They are relatively inefficient in lysing erythrocyte targets, yet are as active as rabbit serum in this assay. Target cell lysis was demonstrated to be via the classical pathway of complement activation. Of the eight 'high complement' mouse strains, four were recently derived from wild mice, and one, SF/CamEi, was derived from wild mice in 1951. The three other strains, BUB/BnJ, DA/HuSn and RIIIS/J, were developed more than 40 years ago, but apparently were not tested previously for complement activity. Using the BUB mouse as a representative of the 'high complement' mice, we assayed levels of the nine complement components, in an attempt to identify the cause of high complement activity. No difference in levels of C1, C2, C4, C8 or C9 was detected between BUB and BDF1 mice. C2 activity was very low in both strains. C3, C5, C6 and C7 activities were higher in BUB mice than in BDF1 mice, indicating that variation in these complement components is responsible for the difference in total complement activity. The genes determining the 'high complement' phenotype appeared to be semi-dominant in F1 hybrids. The 'high-complement' mouse strains, and recombinant strains derived from them, will be useful in a wide range of biomedical research.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2607149     DOI: 10.1016/0022-1759(89)90088-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  49 in total

1.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.

Authors:  Y Matsuoka; M Picciano; B Malester; J LaFrancois; C Zehr; J M Daeschner; J A Olschowka; M I Fonseca; M K O'Banion; A J Tenner; C A Lemere; K Duff
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Use of mouse models to study the mechanisms and consequences of RBC clearance.

Authors:  E A Hod; S A Arinsburg; R O Francis; J E Hendrickson; J C Zimring; S L Spitalnik
Journal:  Vox Sang       Date:  2010-03-21       Impact factor: 2.144

3.  B Cells in Transplantation of Rat, Mouse, and Man.

Authors:  Jeffrey L Platt; Marilia Cascalho
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

4.  A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer.

Authors:  Michelle Elvington; Yuxiang Huang; B Paul Morgan; Fei Qiao; Nico van Rooijen; Carl Atkinson; Stephen Tomlinson
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

5.  Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies.

Authors:  Isabelle Zenklusen; Said Jongo; Salim Abdulla; Kamaka Ramadhani; B Kim Lee Sim; Hayley Cardamone; Erika L Flannery; Thao Nguyen; Matthew Fishbaugher; Ryan W J Steel; Will Betz; Nelly Carmago; Sebastian Mikolajczak; Stefan H I Kappe; Stephen L Hoffman; Brandon K Sack; Claudia Daubenberger
Journal:  J Infect Dis       Date:  2018-04-23       Impact factor: 5.226

6.  Analysis of complement deposition and processing on Chlamydia trachomatis.

Authors:  Mads Lausen; Mikkel Eggert Thomsen; Gunna Christiansen; Nichlas Karred; Allan Stensballe; Tue Bjerg Bennike; Svend Birkelund
Journal:  Med Microbiol Immunol       Date:  2020-11-18       Impact factor: 3.402

7.  Comparison of immunopathology and locomotor recovery in C57BL/6, BUB/BnJ, and NOD-SCID mice after contusion spinal cord injury.

Authors:  Sabina Luchetti; Kevin D Beck; Manuel D Galvan; Richard Silva; Brian J Cummings; Aileen J Anderson
Journal:  J Neurotrauma       Date:  2010-02       Impact factor: 5.269

8.  The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts.

Authors:  Gerald F Späth; L A Garraway; Salvatore J Turco; Stephen M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

9.  Complexity of Complement Resistance Factors Expressed by Acinetobacter baumannii Needed for Survival in Human Serum.

Authors:  Amaro F Sanchez-Larrayoz; Noha M Elhosseiny; Marc G Chevrette; Yang Fu; Peter Giunta; Raúl G Spallanzani; Keerthikka Ravi; Gerald B Pier; Stephen Lory; Tomás Maira-Litrán
Journal:  J Immunol       Date:  2017-08-30       Impact factor: 5.422

10.  Expression of complement system components during aging and amyloid deposition in APP transgenic mice.

Authors:  Julia Reichwald; Simone Danner; Karl-Heinz Wiederhold; Matthias Staufenbiel
Journal:  J Neuroinflammation       Date:  2009-11-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.